ClinicalTrials.gg
CompletedNCT01045421Updated Aug 15, 2016Results posted

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

A Phase 1/2 interventional study of MLN8237 (Alisertib) in Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer and Small Cell Lung Cancer, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-15.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
273
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda — 1 open to participants now, 4 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Takeda.

Enrollment
5th of 17
273 · median 101
Started
2010
the only one that year
Phase 1/2
6 of 31
none open now
Registered
5th of 31
by date

Among the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2010, is one of 6 in phase 1/2, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, or all of them as a file.
02

Study summary

This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.

Read the detailed description

Following the determination of the Recommended Phase 2 Dose (RP2D) and schedule (Phase 1), 20 response-evaluable patients in each of the 5 tumor indications will be enrolled (Phase 2-Stage 1). An interim analysis will determine which tumor indications will proceed to enroll an additional 25 patients (Phase 2-Stage 2) to further evaluate Overall Response Rate (ORR) and other secondary endpoints.

03

Conditions studied

  • Advanced Nonhematological Malignancies
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Metastatic Breast Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Gastroesophageal Adenocarcinoma

Keywords

  • NSCLC
  • SCLC
  • HNSCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

  • 18 years or older
  • or cytologically confirmed and/or advanced solid tumor (Phase 1 only)
  • Phase 2 requires Non-small cell lung cancer (NSCLC); Small-cell lung cancer; Breast adenocarcinoma (female patients only); Squamous cell cancer of the head and neck (HNSCC); or Gastroesophageal adenocarcinoma
  • (ECOG) performance status 0 or 1
  • Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of or abstain from heterosexual intercourse
  • Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse
  • Voluntary written consent
  • Wiling to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures
  • (Phase 2 only)

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Female patients who are pregnant or lactating
  • Serious medical or psychiatric illness that could interfere with protocol completion
  • Receipt of more than 2 previous cytotoxic chemotherapeutic regimens (4 previous regimens for breast cancer). There is no limit on the number of prior noncytotoxic therapies
  • Prior treatment with Aurora A-targeted agents, including MLN8237
  • Prior treatment with high-dose chemotherapy
  • Prior allogeneic bone marrow or other organ transplant
  • Antineoplastic therapy, radiation therapy or any experimental therapy 21 days prior to first dose of MLN8237
  • Symptomatic
  • Radiotherapy to greater than 25% of bone marrow
  • Diagnosis or treatment of another within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected
  • Myocardial infarction within 6 months of enrollment
  • Uncontrolled cardiovascular condition
  • Major surgery within 14 days of first dose of MLN8237
  • Active infection requiring systemic therapy, or other serious infection
  • Inability to swallow oral medication
  • Known history of (HIV) infection, , or
  • Patients requiring full systemic anticoagulation
  • History of uncontrolled sleep apnea syndrome
  • Treatment with enzyme inducers within 14 days prior to the first dose of MLN8237 and during the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
273 participants (actual)

Study arms

  • Experimental
    MLN8237 (Alisertib)

    MLN8237 administered as an enteric-coated tablet (ECT)

    Drug: MLN8237 (Alisertib)

Interventions

  • Phase 1: MLN8237 will be administered orally twice a day on a 7-day dosing schedule Phase 2: MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period.

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)

    Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of the following considered related to alisertib by investigator: Grade 4 neutropenia (absolute neutrophil count \<500 cells/cubic meter \[cells/mm\^3\]) for \>7 days; Grade 4 neutropenia with coincident fever; Grade 4 thrombocytopenia (platelets \<25,000 cells/mm3) for \>7 days; Platelet count \<10,000 cells/mm3; Grade 3 thrombocytopenia with clinically significant bleeding; Delay in initiation of the subsequent therapy cycle by \>7 days due to treatment-related toxicity; \>=Grade 3 nonhematological toxicity except \>=Grade 3 nausea/emesis occurred in the absence of optimal antiemetic therapy; \>=Grade 3 diarrhea occurred in the absence of optimal supportive therapy with loperamide/comparable antidiarrheal; Grade 3 fatigue for \<1 week; Other Grade 3 nonhematological toxicity that could be safely, reliably controlled to \<=Grade 2 with appropriate treatment.

    Time frame: Phase 1: Cycle 1 Day 1 to Cycle 2 Day 21

  2. Phase 2: Percentage of Participants With Objective Response

    Percentage of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 millimeter \[mm\]). No new lesions. PR was defined as greater than or equal to (\>=) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline until complete response or partial response, assessed every 2 cycles up to end of study (up to 50 cycles)

Secondary outcomes

  1. Phase 2: Progression-free Survival (PFS)

    PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. Tumor progression as per RECIST 1.1 was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1or more new lesions is also considered progression.

    Time frame: Baseline until progressive disease, assessed every 2 cycles up to end of study (up to 50 cycles)

  2. Phase 2: Time to Disease Progression (TTP)

    Time in days from start of study treatment to first documentation of objective tumor progression. Tumor progression as per RECIST 1.1 was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1or more new lesions is also considered progression.

    Time frame: Baseline until disease progression, assessed every 2 cycles up to end of study (up to 50 cycles)

  3. Phase 2: Duration of Response (DOR)

    Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response=(the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1). CR: complete disappearance of all target lesions and non-target disease, except nodal disease; all nodes decreased to normal; no new lesions. PR: \>=30% decrease under baseline of the sum of diameters of all target lesions; no unequivocal progression of non-target disease; no new lesions. Tumor progression: \>=20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study); absolute increase of \>=5 mm; appearance of \>=1 new lesions is also considered progression. DOR calculated for the subgroup of participants with objective response.

    Time frame: Baseline up to Week 50

  4. Phase 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events and Serious Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.

    Time frame: Baseline up to 30 days after the last dose of study drug

  5. Phase 1: Cmax- Maximum Observed Plasma Concentration for Alisertib

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours post-dose

  6. Phase 1: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib

    Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

    Time frame: Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose

  7. Phase 1: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib

    Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.

    Time frame: Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose

  8. Phase 1: Terminal Phase Elimination Half-life (T1/2) for Alisertib

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Day 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose

  9. Phase 1: Rac- Accumulation Ratio for Alisertib

    Rac was estimated as a ratio of AUC (0-tau) at Day 7 and AUC (0-tau) at Day 1. Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.

    Time frame: Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose

  10. Phase 1: Peak to Trough Ratio for Alisertib

    Peak to trough ratio was estimated as a ratio of Cmax at Day 7 and the minimum observed plasma concentration (Ctrough) of alisertib at Day 7. Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Ctrough is the minimum plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Day 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose

  11. Phase 1: Steady State Oral Clearance (CLss/F) for Alisertib

    CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-tau), expressed in liter per hour (L/hr).

    Time frame: Day 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose

  12. Phase 2: Relationship Between Clinical Response and Molecular Markers of Response

    In SCLC,chemo-sensitive/resistant population were analyzed;in breast cancers,ER2 and ER2 status were analyzed.HR+ =estrogen receptor-positive or progesterone receptor-positive. HER+ =human epidermal growth factor receptor 2 (HER2). Triple negative =negative for estrogen receptors, progesterone receptors, and HER2.Clinical response according to RECIST version 1.1. CR:complete disappearance of all target lesions,non-target disease,except nodal disease;all nodes decrease to normal (short axis \<10 mm);no new lesions. PR:\>=30% decrease under baseline of the sum of diameters of all target lesions (SLD);short axis was used in the sum for target nodes,longest diameter used in the sum for all other target lesions;no unequivocal progression of non-target disease;no new lesions. Progressive Disease (PD): \>=20% rise in SLD from the smallest value on study;unequivocal progression of existing non-target lesions. Stable Disease (SD):Neither sufficient shrinkage for PR nor sufficient increase for PD.

    Time frame: 12 months

07

Results

Posted Aug 15, 2016

Participant flow

Participants took part in the study at 42 investigative sites in France, Poland, the Czech Republic, and the United States from 16 February 2010 to 25 April 2014.

Phase 1
Participant flow — Phase 1
MilestonePhase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mgPhase 1: MLN8237 60 mgPhase 1: MLN8237 50 mg- Pancreatic CancerPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
Started134123100000
Completed134112100000
Not completed00011000000
Withdrew: Progressive disease00001000000
Withdrew: Withdrawal by subject00010000000
Phase 2
Participant flow — Phase 2
MilestonePhase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mgPhase 1: MLN8237 60 mgPhase 1: MLN8237 50 mg- Pancreatic CancerPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
Started0000005355552660
Completed0000005350532358
Not completed00000005232
Withdrew: Progressive disease00000001111
Withdrew: Death00000001120
Withdrew: Other00000003001

Outcome measures

PrimaryPhase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)

Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of the following considered related to alisertib by investigator: Grade 4 neutropenia (absolute neutrophil count \<500 cells/cubic meter \[cells/mm\^3\]) for \>7 days; Grade 4 neutropenia with coincident fever; Grade 4 thrombocytopenia (platelets \<25,000 cells/mm3) for \>7 days; Platelet count \<10,000 cells/mm3; Grade 3 thrombocytopenia with clinically significant bleeding; Delay in initiation of the subsequent therapy cycle by \>7 days due to treatment-related toxicity; \>=Grade 3 nonhematological toxicity except \>=Grade 3 nausea/emesis occurred in the absence of optimal antiemetic therapy; \>=Grade 3 diarrhea occurred in the absence of optimal supportive therapy with loperamide/comparable antidiarrheal; Grade 3 fatigue for \<1 week; Other Grade 3 nonhematological toxicity that could be safely, reliably controlled to \<=Grade 2 with appropriate treatment.

Time frame:
Phase 1: Cycle 1 Day 1 to Cycle 2 Day 21
Reported as:
Number · participants
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
participantsPhase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mgPhase 1: MLN8237 60 mgPhase 1: MLN8237 50 mg- Pancreatic Cancer
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)000200
PrimaryPhase 2: Percentage of Participants With Objective Response

Percentage of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 millimeter \[mm\]). No new lesions. PR was defined as greater than or equal to (\>=) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline until complete response or partial response, assessed every 2 cycles up to end of study (up to 50 cycles)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Objective Response
percentage of participantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
Phase 2: Percentage of Participants With Objective Response18 (9 to 32)9 (2 to 20)9 (2 to 21)4 (0 to 22)21 (10 to 35)
SecondaryPhase 2: Progression-free Survival (PFS)

PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. Tumor progression as per RECIST 1.1 was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1or more new lesions is also considered progression.

Time frame:
Baseline until progressive disease, assessed every 2 cycles up to end of study (up to 50 cycles)
Reported as:
Median · days
Phase 2: Progression-free Survival (PFS)
daysPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
Phase 2: Progression-free Survival (PFS)164 (78 to 239)49 (41 to 78)72 (43 to 96)92 (72 to 120)49 (42 to 96)
SecondaryPhase 2: Time to Disease Progression (TTP)

Time in days from start of study treatment to first documentation of objective tumor progression. Tumor progression as per RECIST 1.1 was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1or more new lesions is also considered progression.

Time frame:
Baseline until disease progression, assessed every 2 cycles up to end of study (up to 50 cycles)
Reported as:
Median · days
Phase 2: Time to Disease Progression (TTP)
daysPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
Phase 2: Time to Disease Progression (TTP)164 (78 to 239)46 (40 to 86)72 (43 to 96)92 (74 to 144)78 (42 to 114)
SecondaryPhase 2: Duration of Response (DOR)

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response=(the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1). CR: complete disappearance of all target lesions and non-target disease, except nodal disease; all nodes decreased to normal; no new lesions. PR: \>=30% decrease under baseline of the sum of diameters of all target lesions; no unequivocal progression of non-target disease; no new lesions. Tumor progression: \>=20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study); absolute increase of \>=5 mm; appearance of \>=1 new lesions is also considered progression. DOR calculated for the subgroup of participants with objective response.

Time frame:
Baseline up to Week 50
Reported as:
Median · days
Phase 2: Duration of Response (DOR)
daysPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
Phase 2: Duration of Response (DOR)169 (85 to 313)198 (146 to 501)79 (46 to 95)NA (NA to NA)125 (93 to 365)
SecondaryPhase 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events and Serious Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.

Time frame:
Baseline up to 30 days after the last dose of study drug
Reported as:
Number · participants
Phase 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events and Serious Adverse Events
participantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
Adverse Events5252542657
Serious Adverse Events233019828
SecondaryPhase 1: Cmax- Maximum Observed Plasma Concentration for Alisertib

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours post-dose
Reported as:
Geometric mean · nanomole (nM)
Phase 1: Cmax- Maximum Observed Plasma Concentration for Alisertib
nanomole (nM)Phase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mg (Including Pancreatic Cancer)Phase 1: MLN8237 60 mg
Day 1 (n = 1, 3, 4, 13, 3)297602 ± 15949 ± 491619 ± 391696 ± 37
Day 7 (n = 1, 3, 3, 12, 2)9811279 ± 351830 ± 392907 ± 493027 ± NA
SecondaryPhase 1: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib

Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

Time frame:
Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Reported as:
Median · hours
Phase 1: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib
hoursPhase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mg (Including Pancreatic Cancer)Phase 1: MLN8237 60 mg
Day 1 (n = 1, 3, 4, 13, 3)2.92.0 (2 to 2.9)3.2 (2.8 to 6)2.2 (1.7 to 11)6.0 (3 to 7.9)
Day 7 (n = 1, 3, 3, 12, 2)3.13.0 (1 to 6)3.0 (2 to 6)2.4 (0 to 8)2.8 (2.6 to 3.0)
SecondaryPhase 1: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib

Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.

Time frame:
Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Reported as:
Geometric mean · nanomole*hour (nM*hr)
Phase 1: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib
nanomole*hour (nM*hr)Phase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mg (Including Pancreatic Cancer)Phase 1: MLN8237 60 mg
Day 1 (n = 1, 3, 4, 13, 3)26403495 ± 195015 ± 5710736 ± 4813932 ± 42
Day 7 (n = 1, 3, 3, 11, 2)866010184 ± 2413694 ± 5920867 ± 4928709 ± NA
SecondaryPhase 1: Terminal Phase Elimination Half-life (T1/2) for Alisertib

Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

Time frame:
Day 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Reported as:
Mean · hours
Phase 1: Terminal Phase Elimination Half-life (T1/2) for Alisertib
hoursPhase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mg (Including Pancreatic Cancer)Phase 1: MLN8237 60 mg
Phase 1: Terminal Phase Elimination Half-life (T1/2) for Alisertib20.616.0 ± 1.219.0 ± NA20.8 ± 10.327.8 ± NA
SecondaryPhase 1: Rac- Accumulation Ratio for Alisertib

Rac was estimated as a ratio of AUC (0-tau) at Day 7 and AUC (0-tau) at Day 1. Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.

Time frame:
Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Reported as:
Mean · ratio
Phase 1: Rac- Accumulation Ratio for Alisertib
ratioPhase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mg (Including Pancreatic Cancer)Phase 1: MLN8237 60 mg
Phase 1: Rac- Accumulation Ratio for Alisertib3.33.0 ± 1.02.3 ± 0.42.2 ± 0.92.4 ± NA
SecondaryPhase 1: Peak to Trough Ratio for Alisertib

Peak to trough ratio was estimated as a ratio of Cmax at Day 7 and the minimum observed plasma concentration (Ctrough) of alisertib at Day 7. Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Ctrough is the minimum plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Day 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Reported as:
Mean · ratio
Phase 1: Peak to Trough Ratio for Alisertib
ratioPhase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mg (Including Pancreatic Cancer)Phase 1: MLN8237 60 mg
Phase 1: Peak to Trough Ratio for Alisertib1.72.1 ± 0.72.3 ± 1.42.3 ± 0.81.8 ± NA
SecondaryPhase 1: Steady State Oral Clearance (CLss/F) for Alisertib

CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-tau), expressed in liter per hour (L/hr).

Time frame:
Day 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Reported as:
Geometric mean · L/hr
Phase 1: Steady State Oral Clearance (CLss/F) for Alisertib
L/hrPhase 1: MLN8237 10 mgPhase 1: MLN8237 20 mgPhase 1: MLN8237 40 mgPhase 1: MLN8237 50 mg (Including Pancreatic Cancer)Phase 1: MLN8237 60 mg
Phase 1: Steady State Oral Clearance (CLss/F) for Alisertib2.23.8 ± 225.6 ± 724.6 ± 394.0 ± NA
SecondaryPhase 2: Relationship Between Clinical Response and Molecular Markers of Response

In SCLC,chemo-sensitive/resistant population were analyzed;in breast cancers,ER2 and ER2 status were analyzed.HR+ =estrogen receptor-positive or progesterone receptor-positive. HER+ =human epidermal growth factor receptor 2 (HER2). Triple negative =negative for estrogen receptors, progesterone receptors, and HER2.Clinical response according to RECIST version 1.1. CR:complete disappearance of all target lesions,non-target disease,except nodal disease;all nodes decrease to normal (short axis \<10 mm);no new lesions. PR:\>=30% decrease under baseline of the sum of diameters of all target lesions (SLD);short axis was used in the sum for target nodes,longest diameter used in the sum for all other target lesions;no unequivocal progression of non-target disease;no new lesions. Progressive Disease (PD): \>=20% rise in SLD from the smallest value on study;unequivocal progression of existing non-target lesions. Stable Disease (SD):Neither sufficient shrinkage for PR nor sufficient increase for PD.

Time frame:
12 months
Reported as:
Number · percentage of participants
Phase 2: Relationship Between Clinical Response and Molecular Markers of Response
percentage of participantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
HR+: CR (n=26, 0, 0, 0, 0)0 (NA to NA)———NA (NA to NA)
HR+: PR (n=26, 0, 0, 0, 0)23 (9 to 44)———NA (NA to NA)
HR+: SD (n=26, 0, 0, 0, 0)65 (44 to 83)———NA (NA to NA)
HR+: PD (n=26, 0, 0, 0, 0)12 (2 to 30)———NA (NA to NA)
HER+: CR (n=9, 0, 0, 0, 0)0 (NA to NA)———NA (NA to NA)
HER+: PR (n=9, 0, 0, 0, 0)22 (3 to 60)———NA (NA to NA)
HER+: SD (n=9, 0, 0, 0, 0)36 (13 to 65)———NA (NA to NA)
HER+: PD (n=9, 0, 0, 0, 0)44 (14 to 79)———NA (NA to NA)
Triple Negative: CR (n=14, 0, 0, 0, 0)0 (NA to NA)———NA (NA to NA)
Triple Negative: PR (n=14, 0, 0, 0, 0)7 (0 to 34)———NA (NA to NA)
Triple Negative: SD (n=14, 0, 0, 0, 0)36 (13 to 65)———NA (NA to NA)
Triple Negative: PD (n=14, 0, 0, 0, 0)57 (29 to 82)———NA (NA to NA)
Chemotherapy Refractory:CR(n=0,0,0,0,12)NA (NA to NA)———0 (NA to NA)
Chemotherapy Refractory:PR(n=0,0,0,0,12)NA (NA to NA)———25 (5 to 57)
Chemotherapy Refractory:SD(n=0,0,0,0,12)NA (NA to NA)———25 (5 to 57)
Chemotherapy Refractory:PD(n=0,0,0,0,12)NA (NA to NA)———50 (21 to 79)
Chemotherapy Sensitive: CR(n=0,0,0,0,36)NA (NA to NA)———0 (NA to NA)
Chemotherapy Sensitive: PR(n=0,0,0,0,36)NA (NA to NA)———19 (8 to 36)
Chemotherapy Sensitive: SD(n=0,0,0,0,36)NA (NA to NA)———36 (21 to 54)
Chemotherapy Sensitive: PD(n=0,0,0,0,36)NA (NA to NA)———44 (28 to 62)

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: MLN8237- Dose Escalation—13/23 (56.5%)23/23 (100%)
Phase 1: MLN8237 50 mg- Pancreatic Cancer—1/1 (100%)1/1 (100%)
Phase 2: MLN8237 50 mg- Breast Cancer—23/53 (43.4%)52/53 (98.1%)
Phase 2: MLN8237 50 mg- Gastric Cancer—30/55 (54.5%)52/55 (94.5%)
Phase 2: MLN8237 50 mg- HNSCC—19/55 (34.5%)54/55 (98.2%)
Phase 2: MLN8237 50 mg- NSCLC—8/26 (30.8%)26/26 (100%)
Phase 2: MLN8237 50 mg- SCLC—28/60 (46.7%)55/60 (91.7%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventPhase 1: MLN8237- Dose EscalationPhase 1: MLN8237 50 mg- Pancreatic CancerPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
NeutropeniaBlood and lymphatic system disorders2/231/12/532/551/550/262/60
NauseaGastrointestinal disorders2/231/12/530/550/550/260/60
LeukopeniaBlood and lymphatic system disorders1/231/11/531/550/550/260/60
StomatitisGastrointestinal disorders0/231/10/531/551/550/261/60
Flank painMusculoskeletal and connective tissue disorders0/231/10/530/550/550/260/60
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/231/10/530/550/550/260/60
Febrile neutropeniaBlood and lymphatic system disorders3/230/12/532/552/550/264/60
VomitingGastrointestinal disorders3/230/11/531/550/550/261/60
AnaemiaBlood and lymphatic system disorders2/230/12/534/551/553/265/60
Gastrointestinal haemorrhageGastrointestinal disorders2/230/10/532/550/550/260/60
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPhase 1: MLN8237- Dose EscalationPhase 1: MLN8237 50 mg- Pancreatic CancerPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLC
FatigueGeneral disorders13/231/129/5324/5526/5515/2627/60
AnaemiaBlood and lymphatic system disorders4/231/120/5325/5524/5513/2616/60
VomitingGastrointestinal disorders8/231/111/5316/5513/556/2610/60
ThrombocytopeniaBlood and lymphatic system disorders4/231/111/5314/557/556/2611/60
HypokalaemiaMetabolism and nutrition disorders2/231/15/534/552/552/264/60
NeutropeniaBlood and lymphatic system disorders10/230/131/5323/5525/5515/2621/60
Decreased appetiteMetabolism and nutrition disorders13/230/113/5315/5512/555/2618/60
DiarrhoeaGastrointestinal disorders10/230/127/5321/5515/559/2617/60
AlopeciaSkin and subcutaneous tissue disorders10/230/126/5321/5524/5511/2616/60
NauseaGastrointestinal disorders11/230/115/5318/5514/5512/2618/60

Baseline characteristics

Age, Customized
Age, Customized(participants)Phase 1: MLN8237- All ParticipantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLCTotal
18-64 years173733381738180
65-84 years716211792292
85 years and over0010001
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: MLN8237- All ParticipantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLCTotal
Female9531231228117
Male15043521432156
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Phase 1: MLN8237- All ParticipantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLCTotal
Hispanic or Latino34211112
Not Hispanic or Latino194849502557248
Not reported21440213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Phase 1: MLN8237- All ParticipantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLCTotal
White184951532256249
Black or African American31322415
Asian2100104
Chinese0000101
Other0100001
Not reported1110003
Region of Enrollment
Region of Enrollment(participants)Phase 1: MLN8237- All ParticipantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLCTotal
Czech Republic01920871569
France0108113840
Poland0101079
United States242327351630155
Disease stage at study entry
Disease stage at study entry(participants)Phase 1: MLN8237- All ParticipantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLCTotal
IA1000001
II0001001
III1012004
IIIA1100013
IIIB03005210
IIIC0100001
IV19485422157201
IVA100230024
IVB1002003
IVC000250025
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(participants)Phase 1: MLN8237- All ParticipantsPhase 2: MLN8237 50 mg- Breast CancerPhase 2: MLN8237 50 mg- Gastric CancerPhase 2: MLN8237 50 mg- HNSCCPhase 2: MLN8237 50 mg- NSCLCPhase 2: MLN8237 50 mg- SCLCTotal
0423211771385
1203034381947188
08

Study locations

2 sites
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
09

References and documents

Publications

  • Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015 Apr;16(4):395-405. doi: 10.1016/S1470-2045(15)70051-3. Epub 2015 Feb 27. PubMed 25728526 ↗
  • Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs. 2014 Dec;32(6):1181-7. doi: 10.1007/s10637-014-0121-6. Epub 2014 Jun 1. PubMed 24879333 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of May 2013 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2010
First posted
Jan 11, 2010
Start
Feb 2010
Primary completionActual
May 2013
CompletionActual
Apr 2014
Results first posted
Aug 15, 2016
Last update
Aug 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01045421
Responsible party
Sponsor
First posted
Jan 11, 2010
Start date
Feb 2010
Primary completion
May 2013
Completion
Apr 2014
Results posted
Aug 15, 2016
Last update
Aug 15, 2016

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion